Abstracts Archive - Page 323 of 2607 - ACR Meeting Abstracts

Abstract Number: 0380 • ACR Convergence 2024
Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth
Quentin Goossens¹, Christopher Nichols¹, Diana Sofia Villacis-Nunez², Lori Ponder³, Omer Inan⁴ and Sampath Prahalad⁵, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Georgia Institute of Technology, Marietta, GA, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood arthropathy affecting 1 in 1000 children under 16, classified into seven categories by ILAR. Commonly, JIA…
Abstract Number: 0209 • ACR Convergence 2024
Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
Abstract Number: 0174 • ACR Convergence 2024
A Nationwide Analysis of Gender and Racial Disparities in Patients with Systemic Sclerosis and Acute Coronary Syndrome
Omair Khan¹, Kundan Jana², Azka Naeem², Syed Mujtaba Baqir², Marlon Rivera Boadla², Muhammad Hashim khan² and Vijay Shetty², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune condition characterized by widespread skin fibrosis and/or end-organ damage. Previous studies have reported variable outcomes of the disease…
Abstract Number: 0160 • ACR Convergence 2024
Supplement Use in a Diverse Cohort of Individuals with SLE
Russell Ellyson¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Alameda Health System, Highland Hospital, Oakland, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Supplement use among individuals with SLE is not well-characterized, despite potential effects of some supplements on SLE activity or on treatments for SLE or…
Abstract Number: 0136 • ACR Convergence 2024
Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network
Federico Zazzetti¹, Urbano Sbarigia², William Giovanini³, Claire Blacketer⁴, Michel van Speybroeck⁵, Teresa A. Simon⁶, Guo Li³, Chetan S. Karyekar⁴, Reyhan Sonmez⁷, Manuel Ugarte-Gil⁸, RV, Gamboa-Cardenas⁹, Victor Pimentel-Quiroz¹⁰, Guillermo Pons-Estel¹¹, Bernardo Pons-Estel¹², Rosana Quintana¹³, Veronica Saurit¹⁴, ODIRLEI MONTICIELO¹⁵, Katiuzka Zuñiga Corrales¹⁶, Jorge Esquivel-Valerio¹⁷, Martin Rebella¹⁸, Cecilia Pisoni¹⁹, Francinne Machado Ribeiro²⁰, Carlos Núñez-Álvarez²¹, Kaleb Michaud²², Patricia Katz²³, Rangi Kandane-Rathnayake²⁴, Eric Morand²⁵, Worawit Louthrenoo²⁶, Yi-Hsing Chen²⁷, Jiacai Cho²⁸, Laniyati Hamijoyo²⁹, Shue Fen Luo³⁰, Yeong-Jian Jan Wu³⁰, Sandra Navarra³¹, Sargunan Sockalingam³², Masayoshi Harigai³³, Zhuoli Zhang³⁴, BMDB Basnayake³⁵, Madelynn Chan³⁶, Tsutomu Takeuchi³⁷, Sang-Cheol Bae³⁸, Fiona Goldblatt³⁹, Sean O'Neill⁴⁰, Kristine (Pek Ling) Ng⁴¹, Yih Jia Poh⁴², Nicola Tugnet⁴³, Sunil Kumar⁴⁴, Michael Tee⁴⁵, Yoshiya Tanaka⁴⁶ and Chak Sing. Lau⁴⁷, Alberta Hoi⁴⁸, Mandana Nikpour⁴⁹, Mark Sapsford⁵⁰, Íñigo Rúa-Figueroa⁵⁰, José María Pego-Reigosa⁵¹, María Galindo-Izquierdo⁵², Jaime Calvo-Alén⁵³, Antonio Fernández-Nebro⁵⁴, Raúl Menor Almagro⁵⁵ and Frederic Lavie⁵⁶, ¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Physicians Research Center, LLC, Toms River, NJ, ⁷EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ⁹Universidad Científica del Sur, Lima, Lima, Peru, ¹⁰Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ¹³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁴hospital privado universitario de cordoba, Córdoba, Argentina, ¹⁵HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁶Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ¹⁷Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ¹⁸Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ¹⁹CEMIC, Buenos Aires, Argentina, ²⁰Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²²University of Nebraska Medical Center, Omaha, NE, ²³University of California San Francisco, San Francisco, CA, ²⁴Monash University, Clayton, Victoria, Australia, ²⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²⁶Chiang Mai University, Chang Wat Chiang Mai, Thailand, ²⁷Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ²⁸National University Hospital, Kent Ridge, Singapore, ²⁹University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, ³⁰Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), ³¹University of Santo Tomas, Manila, Philippines, ³²University of Malaya Medical Centre, Kuala Lumpur, Malaysia, ³³Tokyo Women's Medical University, Tokyo, Japan, ³⁴Peking University First Hospital, Beijing, China, ³⁵Teaching Hospital, Kandy, Sri Lanka, ³⁶Tan Tock Seng Hospital, Singapore, Singapore, ³⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ³⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³⁹Flinders Medical Centre, Adelaide, Australia, ⁴⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ⁴¹Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, ⁴²SingHealth, Singapore, Singapore, ⁴³Auckland District Health Board, Auckland, New Zealand, ⁴⁴Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, ⁴⁵University of the Philippines, Manila, Philippines, ⁴⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴⁷University of Hong Kong, Pok Fu Lam, Hong Kong, ⁴⁸Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ⁴⁹The University of Sydney, Melbourne, Victoria, Australia, ⁵⁰Middlemore Hospital, Auckland, New Zealand, ⁵⁰Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁶Galicia Health Service (SERGAS), Vigo, Spain, ⁵²Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵³Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁵⁴Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ⁵⁵Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁵⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…
Abstract Number: 0208 • ACR Convergence 2024
Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study
Hajar Elhani¹, abderrahim majjad², Leila Taoubane³, Najlae Elouardi¹, Hamza Toufik⁴ and AHMED BEZZA⁵, ¹Mohamed V Military Training Hospital, Rheumatology, Rabat, Morocco, Rabat, Morocco, ²military hospital of rabat, rabat, Morocco, ³Mohamed V Military Training Hospital, Rheumatology, Rabat, Morocco, Rabat, ⁴Mohamed V Military Training Hospital, Rheumatology, Rabat, Rabat, Morocco, ⁵Hopital Militaire Med V RABAT, Rabat, Morocco
Background/Purpose: The COVID-19 pandemic has heightened concerns regarding the susceptibility of immunocompromised patients, particularly those with autoimmune diseases like rheumatoid arthritis (RA). Early recommendations from…
Abstract Number: 0379 • ACR Convergence 2024
Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children
Athimalaipet Ramanan¹, Catherine Guly², Gabriele Simonini³, Stuart Keller⁴, Priyanka Sen⁴, Thorsten Holzkaemper⁴ and PIERRE QUARTIER⁵, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ³Meyer Children’s Hospital IRCCS; University of Florence, Florence, Toscana, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…
Abstract Number: 0140 • ACR Convergence 2024
Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas
Fabiola Atzeni¹, Fabio Cacciapaglia², Elena Bartoloni Bocci³, Matteo Piga⁴, Garifallia Sakellariou⁵, Ombretta Viapiana⁶, Alessandro Giollo⁷, SIMONE PARISI⁸, Maria Sole Chimenti⁹, Ennio Giulio Favalli¹⁰, Addolorata Corrado¹¹, Eleonora Celletti¹², Ivan Giovannini¹³, Serena Guiducci¹⁴, Elisa Gremese¹⁵, Andreina Manfredi¹⁶, Francesca Romana Spinelli¹⁷ and Gian Luca Erre¹⁸, and "Cardiovascular Obesity and Rheumatic DISeaases" Study Group of the Italian Society of Rheumatology, ¹University of Messina, Italy, Messina, Italy, ²Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ³Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁴Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁵Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁶Rheumatology Unit, University of Verona, Verona, Italy, ⁷Azienda Ospedale Università Padova, Padova, Padua, Italy, ⁸Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ¹⁰ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹¹Rheumatology Unit, University of Foggia, Foggia, Italy, ¹²Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴University of Florence, Pistoia, Italy, ¹⁵Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁶University of Modena and Reggio Emilia, Modena, ¹⁷Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁸Rheumatology Unit - University of Sassari, Sassari, Italy
Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…
Abstract Number: 0375 • ACR Convergence 2024
Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Zineb Aouhab⁹, Swamy Venuturupalli¹⁰, Daniel Wallace¹¹, rosalind Ramsey-Goldman¹², Alfred Kim¹³, Maureen McMahon¹⁴, S. Sam Lim¹⁵, Kalpana Bhairavarasu¹⁶, Alexa Meara¹⁷, Kenneth Kalunian¹⁸ and Cathy Lee Ching¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹Loyola University Medical Center, Oak Brook, IL, ¹⁰Attune Health, Beverly Hills, CA, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Northwestern University, Chicago, IL, ¹³Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁵Emory University, Atlanta, GA, ¹⁶Baylor College of Medicine, Sugar Land, TX, ¹⁷The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁸University of California San Diego, La Jolla, CA, ¹⁹UMMC, Jackson, MS
Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 0195 • ACR Convergence 2024
Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study
S. Sam Lim¹, Vijay R. Nadipelli², Michelle Bruno³, Daphne Lew⁴, Bernard Rubin⁵, Charmayne M. Dunlop-Thomas⁶, Kristi R. Mitchell³, Lydia Demetriou⁷, Jeffrey Berko³ and Alfred Kim⁸, ¹Emory University, Atlanta, GA, ²GSK, Medical Evidence Generation, Philadelphia, PA, ³Atlas Clarity, LLC, San Francisco, CA, ⁴Center for Biostatistics and Data Science, Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine and Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ⁵Progentec Diagnostics, Inc., Oklahoma City, OK, ⁶Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁷GSK, Global Clinical Operations, Brentford, United Kingdom, ⁸Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO
Background/Purpose: Currently, social determinants of health (SDoH; conditions in which people live) are not routinely screened for in US outpatient rheumatology clinics.1 SLE disproportionally affects…
Abstract Number: 0197 • ACR Convergence 2024
Characterizing Diet and Neighborhood Resources in Patients with Systemic Lupus Erythematosus
Justin Arnold¹, Dominique Kinnett-Hopkins², Linda Van Horn¹, Grace Whiteford¹, Lutfiyya Muhammad³, Jing Song⁴, Joan Chmiel¹, Anh Chung⁵, Daniel Erickson¹, Holly Milaeger¹, Christie Bartels⁶, Linda Ehrlich-Jones⁷ and rosalind Ramsey-Goldman¹, ¹Northwestern University, Chicago, IL, ²University of Michigan, Ann Arbor, MI, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University, Worthington, MN, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Shirley Ryan Ability Lab, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory, autoimmune disease that can present with pervasive self-reported fatigue, which negatively impacts the lives of most…
Abstract Number: 0218 • ACR Convergence 2024
Incidental Findings on Whole Body 18F-FDG PET/CT in a Rheumatoid Arthritis Clinical Trial Population
Christina Costeas¹, Daniel Solomon², Katherine Liao³, Jon Giles⁴, Joan Bathon⁵ and Jane Kang⁶, and the TARGET Trial Consortium, ¹Columbia University Irving Medical Center, New York, NY, ²Brigham and Women's Hospital, Newton, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Columbia University, NEW YORK, NY, ⁶Columbia University Medical Center, New York, NY
Background/Purpose: Performing whole body imaging inevitably reveals incidental findings in the majority of cases. A clinical trial was conducted to determine whether different treatment strategies…
Abstract Number: 0161 • ACR Convergence 2024
Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022
malay rathod¹, Eva Kalra², Rafael Sanchez-Dopazo,³, Janmay Vala⁴, Saif Syed⁵, Akhilesh Sharma⁶, Ashwinikumar Shandilya⁷, Asmita Gera⁸, Mohit Lakkimsetti⁹, Juhi Patel¹⁰, VISHRANT AMIN¹¹ and Hardik Desai¹², ¹Monmouth Medical Center, Rutgers University, Ewing, NJ, ²Trident Medical Cente, Charleston, SC, ³Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ⁴Terna Medical College, Navi Mumbai, Maharashtra, India, ⁵Royal college of Surgeons,Dublin,Ireland, Dublin, Dublin, Ireland, ⁶Adesh Institute of Medical Sciences and Research, Bhatinda, India, ⁷Rural Medical college. Pravara institute of medical sciences., Ahmednagar, India, ⁸Tianjin medical University, Tianjin, China, Tianjin, Tianjin, China (People's Republic), ⁹Mamata Medical College,Khammam, Khammam, Telangana, India, ¹⁰GMERS MEDICAL COLLEGE VALSAD, 382330, Gujarat, India, ¹¹GMERS MEDICAL COLLEGE VALSAD, Ahmedabad, India, ¹²Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Osteoarthritis (OA) poses a significant and escalating health challenge across Latin America and the Caribbean (LAC), driven by demographic shifts, lifestyle factors, and varying…
Abstract Number: 0186 • ACR Convergence 2024
Development of a Novel Dried Blood Spot Method to Improve Capacity for ANA Testing in Lower-Resource Settings
Ekemini Ogbu¹, Stela Florea², Donna Diorio², Somak Roy², Dhriti Sharma², Michael Henrickson², Patricia Vega-Fernandez², Angela Migowa³, Sarangarajan Ranganathan² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³AGA KHAN UNIVERSITY, Nairobi, Kenya
Background/Purpose: Timely diagnosis of children and young adults with rheumatologic disorders remains a global challenge especially in lower-resource settings. There is limited access to diagnostic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].